Literature DB >> 22371632

Role of cytokines and chemokines in non-alcoholic fatty liver disease.

Vincent Braunersreuther1, Giorgio Luciano Viviani, François Mach, Fabrizio Montecucco.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLD.

Entities:  

Keywords:  Chemokine; Cytokine; Inflammation; Non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2012        PMID: 22371632      PMCID: PMC3286135          DOI: 10.3748/wjg.v18.i8.727

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  109 in total

1.  Gene expression in human NAFLD.

Authors:  Dario Greco; Anna Kotronen; Jukka Westerbacka; Oscar Puig; Perttu Arkkila; Tuula Kiviluoto; Saara Laitinen; Maria Kolak; Rachel M Fisher; Anders Hamsten; Petri Auvinen; Hannele Yki-Järvinen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-03       Impact factor: 4.052

2.  Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation.

Authors:  Georgi Kirovski; Erwin Gäbele; Christoph Dorn; Lukas Moleda; Christoph Niessen; Thomas S Weiss; Hella Wobser; Doris Schacherer; Christa Buechler; Hermann E Wasmuth; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2010-08-02

3.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

Authors:  John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust
Journal:  J Hepatol       Date:  2006-03-20       Impact factor: 25.083

4.  Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice.

Authors:  Yukinori Tamura; Masayuki Sugimoto; Toshinori Murayama; Yukihiko Ueda; Hiroshi Kanamori; Koh Ono; Hiroyuki Ariyasu; Takashi Akamizu; Toru Kita; Masayuki Yokode; Hidenori Arai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-25       Impact factor: 8.311

5.  Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss.

Authors:  P Dandona; R Weinstock; K Thusu; E Abdel-Rahman; A Aljada; T Wadden
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

6.  Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men.

Authors:  Jens M Bruun; Camilla Verdich; Søren Toubro; Arne Astrup; Bjørn Richelsen
Journal:  Eur J Endocrinol       Date:  2003-05       Impact factor: 6.664

7.  Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents.

Authors:  Valeria Calcaterra; Mara De Amici; Catherine Klersy; Cristina Torre; Vincenza Brizzi; Francesca Scaglia; Michela Albanesi; Riccardo Albertini; Benedetta Allais; Daniela Larizza
Journal:  Acta Biomed       Date:  2009-08

8.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration.

Authors:  Robert F Schwabe; Ramon Bataller; David A Brenner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-06-26       Impact factor: 4.052

10.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

View more
  115 in total

1.  Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis.

Authors:  Mohamed A Abdelmegeed; Atrayee Banerjee; Seong-Ho Yoo; Sehwan Jang; Frank J Gonzalez; Byoung-Joon Song
Journal:  J Hepatol       Date:  2012-06-02       Impact factor: 25.083

2.  Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.

Authors:  David J Orlicky; Andrew E Libby; Elise S Bales; Rachel H McMahan; Jenifer Monks; Francisco G La Rosa; James L McManaman
Journal:  J Physiol       Date:  2019-01-02       Impact factor: 5.182

Review 3.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 5.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

Review 6.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 7.  Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

8.  Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis.

Authors:  Michael J Duryee; Monte S Willis; Courtney S Schaffert; Roger D Reidelberger; Anand Dusad; Daniel R Anderson; Lynell W Klassen; Geoffrey M Thiele
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

9.  NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.

Authors:  Alexander Wree; Matthew D McGeough; Maria Eugenia Inzaugarat; Akiko Eguchi; Susanne Schuster; Casey D Johnson; Carla A Peña; Lukas J Geisler; Bettina G Papouchado; Hal M Hoffman; Ariel E Feldstein
Journal:  Hepatology       Date:  2017-12-28       Impact factor: 17.425

Review 10.  Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management.

Authors:  Vishnubhotla Venkata Ravi Kanth; Mitnala Sasikala; Mithun Sharma; Padaki Nagaraja Rao; Duvvuru Nageshwar Reddy
Journal:  World J Hepatol       Date:  2016-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.